Search Results
Search for other papers by Vincenza Leone in
Google Scholar
PubMed
Search for other papers by Concetta Langella in
Google Scholar
PubMed
Search for other papers by Francesco Esposito in
Google Scholar
PubMed
Search for other papers by Marco De Martino in
Google Scholar
PubMed
Search for other papers by Myriam Decaussin-Petrucci in
Google Scholar
PubMed
Search for other papers by Gennaro Chiappetta in
Google Scholar
PubMed
Search for other papers by Antonio Bianco in
Google Scholar
PubMed
Instituto Nacional de Cancer (INCA), Rio de Janeiro, Brazil
Search for other papers by Alfredo Fusco in
Google Scholar
PubMed
We have previously studied the function of microRNAs (miRNAs) in thyroid cells using the differentiated rat thyroid PC Cl 3 cells that need thyrotropin (TSH) for their growth. The miRNA expression profile examination allowed the detection of a set of miRNAs downregulated and upregulated by TSH. Here, we first demonstrated that upregulation of miR-130b-3p occurs through a protein kinase A-cAMP-responsive element binding protein (CREB)-dependent mechanism. Then, we analyzed its expression in human thyroid follicular adenomas, where a constitutive CREB activation is frequently present. miR-130b-3p results in upregulation with a high fold-change in most thyroid follicular adenomas. Then, we identified CCDC6, coding for a protein that interacts with CREB1 leading to the transcriptional repression of CREB1 target genes, as a target of this miRNA. The targeting of CCDC6 by miR-130b-3p likely accounts for the mechanism by which its upregulation contributes to the development of thyroid adenomas increasing CREB1 activity.
Search for other papers by Matthieu Bosset in
Google Scholar
PubMed
Search for other papers by Maxime Bonjour in
Google Scholar
PubMed
Search for other papers by Solène Castellnou in
Google Scholar
PubMed
Search for other papers by Zakia Hafdi-Nejjari in
Google Scholar
PubMed
Search for other papers by Claire Bournaud-Salinas in
Google Scholar
PubMed
Search for other papers by Myriam Decaussin-Petrucci in
Google Scholar
PubMed
Laboratoire Health Services and Performance Research (EA 7425 HESPER), Université Claude Bernard Lyon 1, Villeurbanne, France
Search for other papers by Jean Christophe Lifante in
Google Scholar
PubMed
Search for other papers by Agnès Perrin in
Google Scholar
PubMed
Search for other papers by Jean-Louis Peix in
Google Scholar
PubMed
CarMeN Laboratory, Université Claude-Bernard Lyon 1, Inserm U1060, INRA U1397, INSA Lyon, IMBL, Villeurbanne, France
Search for other papers by Philippe Moulin in
Google Scholar
PubMed
Search for other papers by Geneviève Sassolas in
Google Scholar
PubMed
Search for other papers by Michel Pugeat in
Google Scholar
PubMed
Registre des Cancers Thyroïdiens du Département du Rhône, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France
Laboratoire Health Services and Performance Research (EA 7425 HESPER), Université Claude Bernard Lyon 1, Villeurbanne, France
Search for other papers by Françoise Borson-Chazot in
Google Scholar
PubMed
Introduction: Recent guidelines of the American Thyroid Association (ATA) suggest that a lobectomy may be sufficient to treat low- to intermediate-risk patients with thyroid tumors ≤40 mm, without extrathyroidal extension or lymph node metastases. The present study aimed to evaluate long-term recurrence after lobectomy for differentiated thyroid cancer and to analyze factors associated with recurrence. Methods: In this retrospective cohort study, patients who underwent a lobectomy for thyroid cancer in a tertiary center between 1970 and 2010 were included. The outcome was the proportion of pathology-confirmed thyroid cancer recurrence, assessed in the whole cohort or in subgroups according to tumor size (≤ or >40 mm). Results: A total of 295 patients were included, and these were followed-up for a mean (standard deviation, SD) 19.1 (7.8) years (5,649 patient-years); 61 (20.7%) were male and the mean (SD) age at diagnosis was 39.7 (12) years. Histological subtype was papillary in 263 (89.2%) patients and mean cancer size was 22.9 (16.9) mm. According to the 2015 ATA guidelines, 271 (91.9%) cancers had a low risk of recurrence and 24 (8.1%) an intermediate risk. A reoperation was performed in 54 patients (18.3%) and recurrence was confirmed in 40 (13.6%), diagnosed for 55% of cases more than 10 years after their initial surgery. Among recurrent patients, 14 (4.8% of the cohort) were operated for a contralateral papillary thyroid microcarcinoma and 26 (8.8% of the cohort) for a locoregional or metastatic recurrence. Non-suspicious nodular recurrences were monitored without reoperation in 53 (18.0%) patients. At the end of follow-up, 282 (95.6%) patients were in remission. Tumors with locoregional or metastatic recurrence were more frequent among tumors with aggressive histology (19.2 vs. 4.1%, p = 0.015) and of intermediate risk category (28.6 vs. 7.1%, p = 0.018). Tumors >40 mm, which would have been treated by thyroidectomy according to the 2015 ATA guidelines criteria, were found in 34 (11.5%) patients and were associated with a higher frequency of recurrence (20.6 vs. 7.3%, p = 0.024) and less remission (85.3 vs. 96.9%, p = 0.001). Conclusion: The outcome of thyroid cancer treated by lobectomy is very good, particularly for cancer ≤40 mm. A prolonged follow-up is required due to the risk of late recurrence.